Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGILENT TECHNOLOGIES, INC.A · Entity 3062 | Director | March 19, 2026 | March 23, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 18, 2020 | May 21, 2020 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | February 24, 2025 | February 25, 2025 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGILENT TECHNOLOGIES, INC.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,800.047 |
Reported balance
After 2026-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 2,158 · Balance 22,800.047 F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock. F2: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 23,857.047 |
Reported balance
After 2026-03-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 1,057 · Balance 23,857.047 F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | IndirectGeorge A. Scangos and Leslie S. Wilson Family Trust | 17,893 |
Reported balance
Holding disclosure · report date 2026-03-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 17,893 F4: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock.
F2: 148.973 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.
F3: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors.
F4: Shares held in the George A. Scangos and Leslie S. Wilson Family Trust.
EXELIXIS, INC.
Report date May 18, 2020 · Filed May 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 714,717 |
Reported balance
After 2020-05-18 transaction · row 1
1 source rowRow 1 · 2020-05-18 · Sale · Disposed 75,000 · Balance 714,717 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (JS) | 8,963 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,963 F3: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Jennifer Scangos Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (KS) | 8,963 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,963 F4: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Katherine Scangos Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,669 |
Reported balance
Holding disclosure · report date 2020-05-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,669 F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.
F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Jennifer Scangos Trust.
F4: Shares held by George A. Scangos and Leslie S. Wilson, as Trustees of the Katherine Scangos Trust.
F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 18, 2020.
Vir Biotechnology, Inc.
Report date February 24, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 698,239 |
Reported balance
After 2025-02-24 transaction · row 1
1 source rowRow 1 · 2025-02-24 · Sale · Disposed 10,056 · Balance 698,239 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,151,730 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,151,730 F2: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,151,730 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,151,730 F4: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 33,629 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 33,629 F5: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 179,930 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 179,930 F6: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 598,270 |
Reported balance
Holding disclosure · report date 2025-02-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 598,270 F3: The shares are held by the spouse of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F2: The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F3: The shares are held by the spouse of the Reporting Person.
F4: The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F5: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F6: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 22, 2022 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 17,726 | $30.65 | $543,303.67 |
DisclosureSEC source: 0001209191-22-011756 · doc4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,989 F2 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 24, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,024 | $31.93 | $320,074.34 |
DisclosureSEC source: 0001209191-22-011756 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,715 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| September 07, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 29,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 9 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,739 Read SEC document |
| September 07, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 877,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 8 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 877,135 F6 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 07, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 61,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 7 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 61,660 F5 · ownership.nature: The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 07, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 877,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 6 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 877,135 F4 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 07, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 61,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 61,660 F3 · ownership.nature: The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees. Read SEC document |
| September 07, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 1,907,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · ownership.nature: On August 30, 2018, the reporting person contributed 1,907,329 shares of the Issuer's common stock to the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "Trust"), a grantor retained annuity trust for the benefit of himself and his children. Upon termination of the Trust, an aggregate of 1,877,590 of the shares were transferred to trusts for the benefit of each of his daughters, of which he and his spouse serve as trustees. The remaining 29,739 shares were distributed to the reporting person. Read SEC document |
| April 01, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 3,598,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,598,559 F1 · ownership.nature: The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011. Read SEC document |
| April 01, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 3,598,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,000 Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 19:26 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 986 | $121.59 | $119,890.70 |
DisclosureSEC source: 0001127602-21-011659 · form4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,543.711 F4 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 19:26 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,850 | $121.59 | $224,947.05 |
DisclosureSEC source: 0001127602-21-011659 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,557.711 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 45.553 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. F3 · balance_after: Number of shares reflects transfer of 14,450 shares from direct holdings to the George A. Scangos and Leslie S. Wilson Family Trust. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 222,000 | $0.00 Strike: $67.38 | $0.00 |
DisclosureSEC source: 0001209191-21-011916 · doc4.xml · derivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires 2031-02-15 F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 111,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011916 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,609,559 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 16, 2021 Filed Feb 14, 2022 21:08 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 900,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009231 · doc5.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,709,559 Read SEC document |
| December 28, 2020 Filed Feb 12, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010199 · doc5.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,498,559 Read SEC document |
| December 02, 2020 Filed Feb 12, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010199 · doc5.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 115,000 F1 · ownership.nature: The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees. Read SEC document |
| December 02, 2020 Filed Feb 12, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GiftCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010199 · doc5.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,598,559 Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:32 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 177 | $93.91 | $16,622.07 |
DisclosureSEC source: 0001127602-20-022976 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,112.158 F1 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. F2 · balance_after: 47.703 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document |
| May 18, 2020 Filed May 21, 2020 00:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 75,000 | $25.96 | $1,947,000.00 |
DisclosureSEC source: 0000939767-20-000086 · wf-form4_159002131982551.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,717 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.59 to $26.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 21,686 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0000939767-20-000084 · wf-form4_158958904987782.xml · derivative · entry 7 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,686 shares Expires 2020-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 21,686 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000939767-20-000084 · wf-form4_158958904987782.xml · derivative · entry 6 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 21,686 | $5.82 | $126,212.52 |
DisclosureSEC source: 0000939767-20-000084 · wf-form4_158958904987782.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $4.58 | $137,400.00 |
DisclosureSEC source: 0000939767-20-000084 · wf-form4_158958904987782.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 25, 2020 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $26.24 | $393,600.00 |
DisclosureSEC source: 0000939767-20-000056 · wf-form4_158777422299168.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.86 to $26.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 55,700 | $26.23 | $1,461,011.00 |
DisclosureSEC source: 0000939767-20-000056 · wf-form4_158777422299168.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.04 to $26.47. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 23, 2020 Filed Apr 25, 2020 00:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 44,300 | $25.68 | $1,137,624.00 |
DisclosureSEC source: 0000939767-20-000056 · wf-form4_158777422299168.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,731 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.04 to $26.03. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 4,200 | $25.05 | $105,210.00 |
DisclosureSEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F6 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.15. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 6 to this Form 4. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 5,800 | $25.04 | $145,232.00 |
DisclosureSEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 4 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,231 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.01 to $25.10. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 5,900 | $24.70 | $145,730.00 |
DisclosureSEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 3 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 863,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.59 to $24.88. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,600 | $24.07 | $616,192.00 |
DisclosureSEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 868,931 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.59 to $24.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 20, 2020 Filed Apr 23, 2020 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 18,500 | $23.39 | $432,715.00 |
DisclosureSEC source: 0000939767-20-000053 · wf-form4_158760303289913.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,531 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.59 to $23.58. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 23:46 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 1,027 | $73.01 | $74,980.24 |
DisclosureSEC source: 0001127602-20-014250 · form4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,887.455 F3 · shares: Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 23:46 UTC | AGILENT TECHNOLOGIES, INC. A · Entity 3062 | GrantCommon Stock | 3,081 | $73.01 | $224,940.73 |
DisclosureSEC source: 0001127602-20-014250 · form4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,860.455 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock. F2 · balance_after: 80.568 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $18.31 | $457,750.00 |
DisclosureSEC source: 0000939767-20-000049 · wf-form4_158716867487658.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person o November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.11 to $18.56. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 236,806 | $29.56 | $6,999,985.36 |
DisclosureSEC source: 0001209191-20-024672 · doc4.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,713,559 F1 · kind: This transaction represents a substitution of assets in which 236,806 shares of the Issuer's common stock were transferred to the reporting person from the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "GRAT") in exchange for other assets. The reporting person was the beneficial owner of the shares while they were held by the GRAT and remains the beneficial owner of the shares following their withdrawal from the GRAT. The reporting person believes that the transfer was exempt under Rule 16a-13 under the Securities Exchange Act of 1934. F2 · price: Represents the average of the reported high and low per share prices for the Issuer's common stock on the date of the transaction. F4 · balance_after: The total number of shares of common stock reported herein as directly owned includes 78,087 shares previously reported as indirectly owned through the GRAT and subsequently distributed to the reporting person in accordance with the terms of the GRAT. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 236,806 | $29.56 | $6,999,985.36 |
DisclosureSEC source: 0001209191-20-024672 · doc4.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,907,329 F1 · kind: This transaction represents a substitution of assets in which 236,806 shares of the Issuer's common stock were transferred to the reporting person from the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "GRAT") in exchange for other assets. The reporting person was the beneficial owner of the shares while they were held by the GRAT and remains the beneficial owner of the shares following their withdrawal from the GRAT. The reporting person believes that the transfer was exempt under Rule 16a-13 under the Securities Exchange Act of 1934. F2 · price: Represents the average of the reported high and low per share prices for the Issuer's common stock on the date of the transaction. F3 · ownership.nature: The shares are held in the name of the GRAT, of which the reporting person and his spouse are trustees. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 7,065 | $18.35 | $129,642.75 |
DisclosureSEC source: 0000939767-20-000048 · wf-form4_158647799860062.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.03 to $18.59. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 07, 2020 Filed Apr 10, 2020 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 16,435 | $18.25 | $299,938.75 |
DisclosureSEC source: 0000939767-20-000048 · wf-form4_158647799860062.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945,096 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.56. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 31, 2020 Filed Apr 3, 2020 00:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 1,500 | $18.06 | $27,090.00 |
DisclosureSEC source: 0000939767-20-000045 · wf-form4_158587246981282.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 961,531 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 18, 2020 Filed Feb 22, 2020 01:28 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 50,000 | $20.73 | $1,036,500.00 |
DisclosureSEC source: 0000939767-20-000028 · wf-form4_158233487004494.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.37 to $21.22. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 01:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 21,000 | $20.02 | $420,420.00 |
DisclosureSEC source: 0000939767-20-000015 · wf-form4_158155686073408.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.08. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 01:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 4,000 | $20.14 | $80,560.00 |
DisclosureSEC source: 0000939767-20-000015 · wf-form4_158155686073408.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.35. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 22, 2020 Filed Jan 25, 2020 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $19.75 | $493,750.00 |
DisclosureSEC source: 0000939767-20-000011 · wf-form4_157991500745631.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.67 to $19.96. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 15, 2020 Filed Jan 18, 2020 01:42 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $20.39 | $509,750.00 |
DisclosureSEC source: 0000939767-20-000008 · wf-form4_157931174373500.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.01 to $20.74. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F3 · balance_after: Adjusted to omit 2,500 shares of Exelixis, Inc. common stock that were mistakenly included in Reporting Person's beneficial ownership reported on prior Form 4 filings. Read SEC document |
| December 27, 2019 Filed Dec 28, 2019 01:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $18.25 | $456,250.00 |
DisclosureSEC source: 0000939767-19-000208 · wf-form4_157749790582072.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,090,531 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.07 to $18.85. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| December 12, 2019 Filed Dec 28, 2019 01:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000208 · wf-form4_157749790582072.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,115,531 Read SEC document |
| August 01, 2019 Filed Aug 3, 2019 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 6,050 | $21.23 | $128,441.50 |
DisclosureSEC source: 0000939767-19-000158 · wf-form4_156479204190426.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.88 to $21.59. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| August 01, 2019 Filed Aug 3, 2019 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 33,950 | $20.48 | $695,296.00 |
DisclosureSEC source: 0000939767-19-000158 · wf-form4_156479204190426.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,134,081 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.85 to $20.76. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| July 01, 2019 Filed Jul 4, 2019 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $21.58 | $863,200.00 |
DisclosureSEC source: 0000939767-19-000146 · wf-form4_156219917418366.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,168,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.40 to $21.79. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.